Roche sets new deadline for Spark acquisition as divestiture speculation brews
To nobody’s surprise at this point, Roche and Spark have extended the offering period of their $4.3 billion buyout deal for another month.
Just days ago the UK Competition and Markets Authority officially sought public comment on the Swiss pharma giant’s competitive position if the deal goes through. As FTC regulators simultaneously conduct their own review, analysts are increasingly convinced that Roche will be forced to abandon a hemophilia gene therapy being developed by Spark in order to consummate the acquisition.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.